Liver cancer relapse prevention after surgery
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two drugs (Donafenib and Envafolimab) after surgery to lower the risk of liver cancer coming back in people who have high-risk features. It may help if you qualify based on your tumor(s) and overall health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 80 years old.
- You must have had surgery for hepatocellular carcinoma (liver cancer) with clear margins (no cancer left behind).
- You must have at least one high-risk feature for the cancer coming back (like a large tumor with microvascular invasion, 3 or more tumors, or a tumor clot in the portal vein).
- You must have good liver function and acceptable blood test results (blood counts, liver and kidney function).
- You must not have had any prior cancer treatment (except antiviral therapy) and must not have other active cancers or autoimmune diseases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving chemotherapy, immunotherapy, and targeted drugs before surgery helps prevent liver cancer from coming back in patients with high-risk tumors. You would receive treatment to shrink the tumor before your scheduled surgery.
This trial tests a drug called Donafenib (a targeted therapy) taken after surgery to see if it can prevent liver cancer from coming back in people at high risk of recurrence.
This early-phase study tests whether adding medicines to ablation (heating/freezing to destroy liver tumors) can keep liver cancer from coming back. It’s for people whose liver cancer recurred after prior surgery/ablation but still fits specific criteria, with the goal of improving disease control.
This trial tests a combination of two drugs, cadonilimab and regorafenib, for people with liver cancer that has worsened after treatment with camrelizumab and apatinib. The goal is to see if this new combination can help control the cancer.
This trial tests a combination of two drugs (donafenib and sintilimab) plus a liver-directed chemotherapy infusion (HAIC) before surgery for liver cancer that can be removed. The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial tests whether giving pembrolizumab (an immune therapy) and lenvatinib (a targeted pill) before planned liver surgery can improve outcomes for people with certain types of operable hepatocellular carcinoma (HCC). It’s meant for tumors that can be removed with curative intent, but still carry a risk of coming back.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.